(Q26745576)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27231906%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

review article

2 references

26 October 2022

NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27231906%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

1 July 2020

metabolic dysfunction–associated steatotic liver disease

1 reference

1 July 2020

1 reference

3 November 2019

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27231906%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1

Luigi Elio Adinolfi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27231906%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

2

Luca Rinaldi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27231906%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

7

Rosa Zampino

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27231906%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

3

Barbara Guerrera

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27231906%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

4

Luciano Restivo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27231906%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

5

Aldo Marrone

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27231906%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

language of work or name

English

0 references

publication date

25 May 2016

8 references

23 March 2019

21 March 2019

3 November 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27231906%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 July 2020

22 October 2022

25 October 2022

26 October 2022

International Journal of Molecular Sciences

8 references

23 March 2019

21 March 2019

3 November 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27231906%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 July 2020

22 October 2022

25 October 2022

26 October 2022

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27231906%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27231906%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution

3 April 2020

page(s)

803

0 references

copyright license

7 references

23 March 2019

21 March 2019

3 November 2019

1 July 2020

22 October 2022

25 October 2022

26 October 2022

0 references

on focus list of Wikimedia project

ScienceSource

0 references

cites work

Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Review article: HCV genotype 3 – the new treatment challenge

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Hepatitis C virus-infected patients are 'spared' from the metabolic syndrome but not from insulin resistance. A comparative study of nonalcoholic fatty liver disease and hepatitis C virus-related steatosis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Steatosis affects chronic hepatitis C progression in a genotype specific way

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

NAFLD: a multisystem disease.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Chronic HCV infection is a risk factor of ischemic stroke

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Development of hepatocellular carcinoma in patients with chronic hepatitis C more than 10 years after sustained virological response to interferon therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Hepatitis C virus to hepatocellular carcinoma.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Metabolic alterations and chronic hepatitis C: treatment strategies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Hepatitis C virus cell entry: role of lipoproteins and cellular receptors

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Activation of sterol regulatory element-binding protein 1c and fatty acid synthase transcription by hepatitis C virus non-structural protein 2.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Chronic hepatitis C and superimposed nonalcoholic fatty liver disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

The spectrum of extrahepatic manifestations in hepatitis C virus infection

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Patatin-Like Phospholipase Domain-Containing 3 I148M Variant Is Associated with Liver Steatosis and Fat Distribution in Chronic Hepatitis B.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

The impact of hepatic steatosis on the natural history of chronic hepatitis C infection

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

High prevalence of hepatitis C virus infection in diabetic patients

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

31 May 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Body composition and hepatic steatosis as precursors of fibrosis in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Morphometric analysis of hepatic steatosis in chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Factors associated with the presence of nonalcoholic steatohepatitis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Microsomal triglyceride transfer protein (MTP) -493G/T gene polymorphism contributes to fat liver accumulation in HCV genotype 3 infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Effect of steatosis and inflammation on liver fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Steatosis in chronic hepatitis C: relationship to the virus and host risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Factors associated with hepatic fibrosis in patients with chronic hepatitis C: a retrospective study of a large cohort of U.S. patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Fibrogenic impact of high serum glucose in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Impact of steatosis on progression of fibrosis in patients with mild hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Hepatic steatosis correlates with the postoperative recurrence of hepatitis C virus-associated hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Prognostic significance of glycaemic control in patients with HBV and HCV-related cirrhosis and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Hepatitis C virus RNA localization in human carotid plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS17060803

Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4926337

Host- and disease-specific factors affecting steatosis in chronic hepatitis C

28 November 2018

1 reference

12 December 2020

Nonalcoholic fatty liver disease

1 reference

12 December 2020

Patatin-like phospholipase domain containing-3 Ile148Met and fibrosis progression after liver transplantation

1 reference

12 December 2020

Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C

1 reference

12 December 2020

Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C

1 reference

12 December 2020

Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis

1 reference

12 December 2020

Identifiers

DOI

10.3390/IJMS17060803

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27231906%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27231906%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

2 references